百奧賽圖邀您共同探討——生物醫藥研發的未來方向

瀏覽次數：8665　發布日期：2019-6-5　來源：本站　本站原創，轉載請注明出處

本次大會由Biocytogen和AcroBiosystem聯合主辦，圍繞生物醫藥以及抗體藥物的發現與發展，致力于為生物醫藥產業做出更多的貢獻。

會議于美國時間2019年6月13日下午1-6點在波士頓召開，屆時歡迎大家蒞臨參會。

Free to attend, light dinner will be provided. Join Biocytogen and AcroBiosystem to learn more about the cutting-edge technologies and latest research in biologic drug development. The symposium is co-organized by Biocytogen and AcroBiosystem, focusing mainly on therapeutic antibody and biologic drug discovery and development.

Theme:Future of Biologic Drug Discovery and Development
Time:June 13th, 1:00 PM - 6:00 PM
Location:Residence Inn Boston Cambridge, 120 Broadway, Six Cambridge Center, Cambridge, MA

Confirmed Speakers

Chun-Nan Chen
CEO and CSO, Single Cell Technology

Qingcong Lin
CEO, Biocytogen Boston Corp

Stephen Gillies
CSO, LinkedUp Bioscience Inc

Johanna Lahdenranta
Director of In Vivo Pharmacology, Bicycle Therapeutics

Xiaodong Li
Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP

Agenda

1:00 PM - 1:20 PM
Registration

1:20 PM - 1:30 PM
Welcome Remark

1:30 PM - 2:00 PM
Introducing AbTheneum, A High Throughput and Data-rich Antibody Discovery Platform by Single Cell Technology
Chun-Nan Chen, CEO and CSO, Single Cell Technology
Named after an institution of great knowledge, AbTheneum™ is Single Cell Technology’s antibody discovery platform. Deploying AbTheneum™, we screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each antibody from single cells. AbTheneum™ screening assay is flexible and can be customized for any target to find cross-reactivity, epitope specificity, and more. Case studies will be shown for anti-BCMA and anti-FOLR1 antibody leads discovered using AbTheneum™ and their validation data. The discovery of these high-quality and therapeutically relevant antibody candidates highlights the power of AbTheneum™.

2:00 PM - 2:30 PM
Accelerating Therapeutic Antibody Candidate Discovery using Biocytogen Humanized Mouse Models
Qingcong Lin, CEO, Biocytogen Boston Corp
The traditional therapeutic antibody discovery is a lengthy, multi-staged process from hit generation, lead screening, optimization to candidate selection. Depending on surrogate antibodies for efficacy tests in animal models has significantly constrained the therapeutic antibody discovery. This presentation will discuss three approaches to expedite the process. First, Biocytogen has generated thirty+ IO checkpoint humanized GEMM, enabling direct testing of anti-human antibodies in mice without depending on mouse cross-reactive antibody candidates. We have also created human CD3 knock-in mice for testing T cell-engaging bispecific antibodies. Second, our proprietary immunodeficient B-NDG and series of B-NDG variant mice are excellent host for engraftment of human PBMC and CD34+ hematopoietic stem cells and allow testing anti-human antibody candidate efficacy and safety. Finally, we have generated RenMab mice, by introducing the complete human heavy chain and light chain V(D)J regions to replace the mouse counterpart loci. A case study, where we considerably shortened the hit to lead process by conducting high-throughput in vivo efficacy-based lead identification using our humanized mice will also be presented.

2:30 PM - 3:00 PM
Humanized Mice for Studies of Immunocytokine Mono and Combi-therapies
Stephen Gillies, CSO, LinkedUp Bioscience Inc

Antibody-cytokine fusion proteins (immunocytokines or IC) target the tumor microenvironment where they stimulate a cascade of immune responses based on their interaction with resident tumor, stroma and infiltrating lymphocytes, macrophage and myeloid cells. The goal is to overcome this immune suppressive environment. Due to species specificity of cytokine and cytokine receptor interactions, the best way is to use murine cytokines in syngeneic tumor models or to use humanized NOG mice with the all human antibody and cytokine molecules being developed as potential drugs. Many years ago, in collaboration with Jackson Labs and the University of Tuebingen, we developed models in which CD34+ human hematopoietic stem cells were adoptively transferred into irradiated NOG mice and given weekly doses of long-lasting IL7 (Fc-IL7). This resulted in mice with high numbers of human B, NK and T cells that quickly develop diverse TCR repertoires and have since been shown to be highly functional in IC-induced anti-tumor efficacy. One such IC, NHS-IL12, contains two molecules of species-specific human IL12 and targets DNA that is released into the necrotic regions of all solid tumors, independent of species. Studies include combination therapies with local radiation or with other cytokines leading to some surprising results.

3:00 PM - 3:30 PM
Coffee Break and Networking

3:30 PM - 4:00 PM
Activation of CD137 Using Multivalent and Tumor Targeted Bicyclic Peptides
Johanna Lahdenranta, Director of In Vivo Pharmacology, Bicycle Therapeutics

4:00 PM - 4:30 PM
Patent Portfolio Development for Biologic Products
Xiaodong Li,Associate of Patent and Intellectual Property, Choate, Hall & Stewart LLP

Biological products are typically protected by patent portfolios comprising a number of patents. Using specific products as examples, Xiaodong will discuss how to use different types of patent filings and claims to provide layered protection for biological products and how to maximize their patent protection. He will share his experience on how to identify inventions at various development and commercial stages and how to protect them accordingly.

4:30 PM – 6:00 PM
Dinner Reception (Light dinner will be provided)

To register for the symposium, please go to "register"

索取資料

相關公司：百奧賽圖（北京）醫藥科技股份有限公司
聯系電話：010-56967680
E-mail：info@bbctg.com.cn

【點擊可查看百奧賽圖（北京）醫藥科技股份有限公司相關服務】

分享到：QQ空間新浪微博騰訊微博微信

【所有新聞】【本類新聞】【相關服務】【關閉窗口】

相關鏈接

本類新聞

關于我們 | 法律聲明 | 廣告報價 | English | 網站地圖

<rt id="wmsrm"></rt>